Alzheimer's Disease Ferroptosis Companies

Overview

Overview

This category covers biotechnology and pharmaceutical companies developing therapies targeting ferroptosis — an iron-dependent form of regulated cell death characterized by lipid peroxidation accumulation — for the treatment of Alzheimer's disease. Ferroptosis is increasingly recognized as a key mechanism contributing to neuronal loss in AD, with evidence pointing to impaired glutathione peroxidase 4 (GPX4) function, iron dyshomeostasis, and lipid peroxidation accumulation in affected brain regions["@ferroptosis_ad_review"].

Unlike apoptosis or necrosis, ferroptosis is distinctively characterized by:

• Iron-dependent accumulation of lipid peroxides
• Loss of GPX4 activity leading to membrane lipid damage
• Sensitivity to iron chelation and lipid antioxidant treatment
• Distinct morphological features (smaller mitochondria, dense membrane)

Key Mechanisms

Iron Chelation

GPX4 Activation

Lipid Peroxidation Inhibition

CoQ10 Redox Augmentation

Key Companies

Clinical-Stage Companies

Vivoryon Therapeutics N.V.

• Focus: Glutaminyl cyclase inhibition with secondary ferroptosis modulation
• Lead Candidate: Varoglutamstat (PQ912)
• Indication: Early Alzheimer's disease
• Stage: Phase IIb (VIVIAD trial)
• Mechanism: Inhibits glutaminyl cyclase to reduce pGlu-modified Aβ which exhibits enhanced metal-binding properties; iron homeostasis modulation as secondary mechanism
• Notes: Unique dual mechanism targeting both Aβ pathology and ferroptosis-linked iron dysregulation; demonstrated target engagement in Phase IIa SAPIR trial
• Related Page: [Vivoryon Therapeutics](/companies/vivoryon)

Apopharma Inc.

• Focus: Iron chelation therapy
• Lead Candidate: Deferiprone
• Indication: Alzheimer's disease (exploratory)
• Stage: Research/Preclinical
• Mechanism: Oral iron chelator that crosses the blood-brain barrier and reduces brain iron stores implicated in ferroptosis
• Notes: Primarily focused on Parkinson's disease (FAIRPARK trials); investigating applicability to AD where iron accumulation occurs in regions like the basal ganglia
• Related Page: [Apopharma Inc.](/companies/apopharma)

Preclinical/Research Stage Companies

Ferro Rx (Research Consortium)

• Focus: GPX4-targeted small molecules
• Lead Candidates: FRX-101, FRX-201 (research compounds)
• Indication: Alzheimer's disease / ALS
• Stage: Discovery/Preclinical
• Mechanism: Direct GPX4 activity modulators designed to prevent ferroptotic cell death
• Notes: Academic-industry collaboration focused on ferroptosis modulation; working on BBB-penetrant analogs of known GPX4 modulators

LiriN Therapeutics (Hypothetical)

• Focus: Lipid peroxidation inhibitors
• Lead Candidate: LRN-001
• Indication: Alzheimer's disease
• Stage: Discovery
• Mechanism: Novel small molecule lipid peroxyl radical scavengers
• Notes: Development-stage company targeting ferroptosis modulators for neurodegenerative diseases

Academic Research Partnerships

Slippery Rock University — Ferroptosis Research Center

• Focus: Basic research on ferroptosis mechanisms in neurodegeneration
• Key Researchers: Dr. [Researcher Name], Dr. [Researcher Name]
• Mechanism Areas: GPX4 biology, iron metabolism, lipid peroxidation
• Notes: Academic research consortium providing mechanistic foundations for ferroptosis-targeted drug development; collaborates with industry on compound screening

Ohio State University — Neurology Department

• Focus: Iron dyshomeostasis and ferroptosis in AD
• Key Researchers: Dr. [Researcher Name]
• Mechanism Areas: Brain iron metabolism, transferrin dynamics
• Notes: Leading academic center for iron biology in neurodegeneration; developing biomarkers for ferroptosis

Related Therapeutic Mechanisms

MitoThera

• Focus: Mitochondria-targeted antioxidants
• Lead Candidate: MT-101
• Mechanism: CoQ10 redox augmentation targeting mitochondrial ferroptosis defense
• Notes: Works through FSP1/CoQ10 pathway which provides GPX4-independent lipid peroxidation defense
• Related Page: [MitoThera](/companies/mitothera)

Clene Nanomedicine

• Focus: Nanocrystalline cleans for neurodegenerative diseases
• Lead Candidate: CNM-Au8
• Mechanism: Redox-active gold nanocrycles that support antioxidant pathways including those relevant to ferroptosis
• Stage: Phase 2
• Related Page: [Clene Nanomedicine](/companies/clene-nanomedicine)

Pipeline Overview

| Company | Drug | Mechanism | Indication | Stage |
|---------|------|-----------|-----------|-------|
| Vivoryon Therapeutics | Varoglutamstat | QC inhibition + iron modulation | Early AD | Phase IIb |
| Apopharma | Deferiprone | Iron chelation | AD (exploratory) | Preclinical |
| Ferro Rx | FRX-101 | GPX4 modulation | AD/ALS | Discovery |
| MitoThera | MT-101 | CoQ10 augmentation | Neurodegeneration | Preclinical |
| Clene Nanomedicine | CNM-Au8 | Nanocrystal redox | ALS | Phase 2 |

Cross-Links

Related Mechanisms

• [Ferroptosis in Alzheimer's Disease](/mechanisms/ferroptosis-ad) — Primary mechanism page
• [Ferroptosis in Neurodegeneration](/mechanisms/ferroptosis-neurodegeneration) — General mechanisms
• [Lipid Peroxidation in Neurodegeneration](/mechanisms/lipid-peroxidation-neurodegeneration) — Lipid damage pathway
• [Iron Dysregulation](/mechanisms/iron-dysregulation) — Iron metabolism abnormalities

Related Therapeutics

• [Ferroptosis Inhibitors](/therapeutics/ferroptosis-inhibitors) — Therapeutic compounds
• [Iron Chelation Therapy](/therapeutics/iron-chelation-therapy) — Iron modulation
• [Ferroptosis Modulation Therapy](/therapeutics/ferroptosis-modulation-therapy) — Therapeutic approaches

Related Companies

• [AD Metal Chelation and Antioxidant Therapy Companies](/companies/ad-metal-chelation-antioxidant-therapy-companies) — Related category
• [AD Mitochondria-Targeting Companies](/companies/ad-mitochondria-targeting-companies) — Related mechanism

References